Sulindac in Preventing Melanoma in Healthy Participants Who Are at Increased Risk of Melanoma
Completed · Phase 2 · Has a placebo group
Conditions studied: Precancerous Condition
In brief
This randomized phase II trial is studying how well sulindac works in preventing melanoma in healthy participants who are at increased risk of melanoma. Sulindac may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether sulindac is more effective than a placebo in preventing melanoma in individuals with many moles and abnormal moles.
Key facts
- Study ID
- NCT00841204
- Run by
- National Cancer Institute (NCI)
- People needed
- 50
- Starts
- 2009-02-01
- Expected to finish
- 2011-02-01
- Last updated by the study team
- 2017-12-26
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.
Where it is running
- University of Arizona Health Sciences Center — Tucson, Arizona, United States
- Stanford University Hospitals and Clinics — Stanford, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.